and thickness of tumour (Breslow, 1970) are known to predict the clinical behaviour of primary melanoma.
Malignant melanoma is known for its varying clinical course and its resistance to most non-surgical therapeutic approaches. A few parameters such as level of invasion (Clark et al., 1969) and thickness of tumour (Breslow, 1970) are known to predict the clinical behaviour of primary melanoma. Flow cytometric analysis of nuclear DNA content and S-phase fraction (SPF) is feasible method of estimating the malignant potential and growth characteristics of various malignant tumours (Seckinger et al., 1989) . In many tumours DNA aneuploidy and high S-phase fraction (SPF) have been reported to correlate with poor prognosis. DNA aneuploid primary melanomas recur earlier than do DNA diploid melanomas (S0ndergaard et al., 1983; Frankfurt et al., 1984; Friedlander et al., 1984; Kheir et al., 1988; von Roenn et al., 1986; Buchner et al., 1985; Lindholm et al., 1989) . DNA aneuploidy has also been associated with shorter survival in primary melanoma (Lindholm et al., 1989; S0ndergaard et al., 1983) . Patients with DNA aneuploid metastatic melanoma have also in one report been found to have a worse prognosis than patients with DNA diploid tumours (S0nder-gaard et al., 1983) , while in another study there was no association of DNA ploidy but only of the S-phase fraction with prognosis (Hansson et al., 1982) .
We have correlated the flow cytometrically determined DNA ploidy and S-phase fraction with the prognosis of patients with metastatic melanoma. As some of the observations were unexpected these will be further compared with similar findings in other malignancies.
Material and methods

Patients
The study population consisted of 95 consecutive patients (58 male, 37 female) with metastatic melanoma treated and subsequently followed up and August 1990. The biopsies were taken when a relapse after primary surgery was suspected. The major characteristics of the patients are presented in Table I .
Follow-up After the metastatic disease was diagnosed the patients were routinely followed in either of the above mentioned hospitals for up to 5 years. The majority of the patients were treated according to various trial protocols. Systemic chemotherapy and/or interferon therapy was given to 44 patients, while 51 patients received only local radiotherapy or no therapy in addition to surgery. The systemic first-line treatments were sequentially as follows: cisplatin + etoposide (1982) (1983) , leucocyte alpha interferon (1984) (1985) (1986) (1987) (1988) and interferon + four-drug chemotherapy from December 1988 onwards. The time and cause of death were recovered from hospital files Vindel0v et al., 1983) . The pellet was resuspended by addition of 0.5 ml of ethidium bromide (50 Lg ml-' in 1O mM Tris buffer, 1 mM EDTA, 0.3% Nonident P40, pH 7.5). The tube was vortexed and held on ice for 15 min. Then 0.25 ml of a solution containing 1 mg ml-' RNAase (Sigma) was added to the tube and incubated for 15 min at room temperature. Immediately before analysis the sample was filtered through a 30 Jm nylon mesh.
Ten samples were prepared from paraffin-embedded material according to the procedure described previously (Kouri et al., 1990) .
Routinely 15,000 cells per sample were analysed with an EPICS C flow cytometer (Coulter, Hialeah, Florida) . A 2-Wargon ion laser was used for excitation at a wavelength of 488 nm, and the total emission above 590 nm was measured. The mean coefficient of variation of the diploid peak was 5.11 (s.d. 2.27).
The flow cytometric parameters evaluated included the DNA ploidy and DNA index (DI, where DI represents the ratio of the aneuploid stem line GI DNA peak channel to diploid stem line G1-DNA peak channel). Tumours were classified as aneuploid if there was a second GI-peak in addition to the diploid GI-peak. Aneuploid tumours with a DI between 1.9 and 2.1 and a definable S-and G2M-phase were defined as tetraploid. The S-phase fraction (SPF) was calculated as described previously (Pyrh6nen et al., 1991) .
When multiple samples per patient were available the mean SPF value was used, and the DNA ploidy of the patient was coded as the most deviant DNA ploidy among the samples. Samples with a coefficient of variation greater than 8.0% or with a large amount of debris or with near diploid aneuploidy were excluded from the cell cycle analysis. Since the distribution of SPF values differed significantly between DNA diploid and aneuploid tumours, a new parameter SPF index was calculated, dividing the SPF values into two groups based on whether the individual patients' SPF was over or under the median SPF of his DNA ploidy group.
Statistical methods
Differences between mean values were analysed using Student's t-test, and differences between frequencies using the contingency tables.
For calculation of survival after metastases product limit survival analysis was performed using the BMDP IL computer program (Dixon, 1988) . Brookmeyer-Crawley 95% confidence limits for median survival time are reported. Calculations of the significance of observed differences were performed using the log rank test (Mantel-Cox). P-values under 0.05 were considered significant. Cox multivariate analysis was performed using DNA ploidy, SPF index, TNM stage, sex, age and tumour pigmentation as covariates.
Results
Ploidy and S-phasefraction A single diploid clone was seen in 33 patients, while 43 other patients had a single aneuploid clone in addition to the diploid one. A further six patients had a tetraploid clone, and 13 showed multiple aneuploid clones. The proportion of diploid samples was comparable in fresh histological specimens (37/107), paraffin embedded specimens (7/10) and fine needle aspirates (7/18).
The S-phase fraction was calculable for 74 patients. The DNA diploid tumours (n = 31) showed a significantly (P<0.0002) lower SPF than those which were DNA aneuploid (n = 43) median 10.3 and 15.5, respectively. The mean SPF of fresh histological specimens was essentially equal to that of paraffin embedded material and fine needle aspirates, 14.4, 15.4 and 14.1, respectively.
Survival afterfirst recurrence
Patients with DNA diploid tumours had a worse prognosis (median survival 16 months) after the first recurrence than did patients with DNA aneuploid tumours (median survival 28 months) (Figure 1 , Table II ). This difference was even more prominent among patients receiving systemic therapy and patients with stage IV disease (Table II) .
The S-phase fraction alone was not a significant prognostic factor since the aneuploid tumours had significantly higher SPF but more favourable prognosis. When the imbalance between different DNA ploidies' SPF was controlled for by adjusting the individual SPF with respect to the median SPF of each respective DNA ploidy group SPF index was also a highly significant prognostic factor (Figure 2) . SPF above the median was the most important determinant of poor prognosis in Cox's multivariate analysis (P<0.002), followed by TNM stage IV and DNA diploidy (P<0.05), when age, sex and tumour pigmentation were analysed as covariates. Figure 2 Cumulative proportion of melanoma patients surviving after appearance of first metastases. Patients with SPF below or at the median ( * , n = 38) have significantly better prognosis than patients with SPF above the median (-O-, n = 36). P = 0.002, product limit, Mantel-Cox.
Discussion
In the present study of the prognostic value of DNA ploidy and S-phase fraction in 95 metastatic melanoma patients, DNA aneuploidy and low S-phase fraction were observed to predict longer survival after the first metastases have appeared. The observation of DNA aneuploidy as a favourable feature is in contrast to the earlier report on metastatic melanoma (S0ndergaard et al., 1983) and conflicts with those concerning primary melanomas (Frankfurt et al., 1984; Buchner et al., 1985; Hansson et al., 1982; Sondergaard et al., 1983) . Our data confirm the previous report by Hansson et al. (1982) on poor prognosis of metastatic melanoma patients with high SPF.
In many solid tumours some disagreement exists on the prognostic value of DNA ploidy (Kouri et al., 1990; Kallioniemi, 1988; Volm et al., 1985; Zimmerman et al., 1987; Tirindelli-Danesi et al., 1987; Look et al., 1984) . Frequently, DNA aneuploid tumours have more readily been associated with unfavourable prognosis than have DNA diploid tumours. This has not, however, been a consistent finding. In some cases, no difference in prognosis between DNA diploid and aneuploid tumours has been observed (Kallioniemi, 1988) or the opposite result (of DNA aneuploidy being a favourable sign) has been reported (Goldsmith et al., 1986) .
The systemic treatment given to the patients varied sequentially during the study period. At the early years of the study cis-platinum + etoposide was used as first line treatment, later substituted by interferon alfa and most recently by a four-drug chemotherapy in combination with interferon (manuscript under preparation) . Principally all the patients with inoperable tumours and eligible to aforementioned protocols were treated with systemic therapy. No adjuvant treatment was used for those receiving radical operations. DNA aneuploidy correlated with favourable prognosis only among patients receiving systemic therapy. Since the patients were given systemic therapy irrespective of DNA ploidy, this may indirectly indicate a better response to therapy of DNA aneuploid tumours. Anyhow, although the decision to treat a patient systemically was not based on flow cytometric parameters, the other prognostic factors are not necessarily balanced in the two treatment groups. DNA aneuploid neuroblastomas (Look et al., 1984) have been reported to be more sensitive to chemotherapy than DNA diploid ones. Also regarding microcellular lung carcinoma near-diploid type tumours might be more resistant to chemotherapy than are hyperdiploid tumours (Abe et al., 1987) . Interestingly, similar phenomenon to these have been observed in radiosen-sitivity of other malignancies: DNA aneuploid laryngeal carcinomas (Goldsmith et al., 1986) , carcinomas of the oral cavities (Franzen et al., 1987) and the uterine cervix (Dyson et al., 1987) , as well as bladder carcinomas (Jacobsen et al., 1987) have been reported as more radiosensitive than DNA diploid tumours. This probably has been contributed to a better prognosis for patients with DNA aneuploid tumours after curative radiotherapy in these tumour groups (Goldsmith et al., 1986; Franzen et al., 1987) . On the other hand, in most of the studies concerning tumours treated primarily by surgery, such as breast cancer and colorectal malignancies, DNA aneuploidy indicates a less favourable prognosis (Kallioniemi, 1988) . In malignant melanomas the significance of DNA ploidy in different treatment modalities is unknown, and cannot yet be estimated in this study due to our limited number of patients.
Like the DNA ploidy pattern, SPF has been described as having prognostic value for solid tumours (Kallioniemi, 1988) . In the present study, low SPF was observed to be an indicator of a good prognosis. Patients with SPF at or below median SPF had a median survival twice as long as did those with high SPF. The observation is in harmony with earlier reports on melanomas (Hansson et al., 1982) and many other malignancies (Kallioniemi, 1988) .
It remains to be determined whether flow cytometric parameters may be used as a guideline for selecting a treatment strategy for each patient. Further expansion of this study and a detailed analysis of patients receiving chemotherapy or a new highly promising combination of chemotherapy plus interferon (manuscript under preparation) will hopefully provide more information in this respect.
The flow cytometric method is rapid and practicable for analysing certain biologic features of human tumours, such as DNA ploidy pattern and proliferation characteristics. We found that, in contrast to earlier findings in primary melanoma, DNA aneuploidy in metastatic melanoma is an indicator of favourable prognosis especially among patients receiving systemic therapy. The favourable prognosis of patients with low SPF was also demonstrated. We thus conclude that flow cytometric data may contribute to the difficult task of selecting patients for various treatment or follow-up protocols.
